ANRS COV-POPART vaccination cohort
Last updated on 24 September 2025
Main points
- COV-POPART is a French national multicentre cohort study whose objective is to evaluate the humoral immune response to Covid-19 vaccination in a standardised manner in each subpopulation.
- This cohort study involves the prospective collection of clinical data and the creation of a collection of biological samples (biobanks) with the aim of evaluating the response to Covid-19 vaccination.
- This study is being conducted among various sub-populations considered to be ‘at risk’ and among a “control” population (not considered to be ‘at risk’).
Primary objective
To evaluate the humoral immune response to Covid-19 vaccination in a standardised manner in each subpopulation:
- At 1, 6, 12, and 24 months after the single injection (initial single-injection schedule),
- At the time of the second injection and then 1, 6, 12 and 24 months after the second vaccine injection (initial two- or three-injection schedules) and,
- One month after the third injection in participants receiving a third injection as part of their initial vaccination schedule, in accordance with current recommendations.
In brief
Planning
Start dates: 25/03/2021
End date of research: 11/12/2024
Number of participants recruited/expected
6072 / 6500
Status
Completed
Sponsorship
Inserm-ANRS MIE
Publications
- Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay JY, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021 Aug;27(8):1319-1321. doi: 10.1038/s41591-021-01435-1. PMID: 34253930.
- Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay JY, et al; ANRS0001S COV-POPART study group. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort. Clin Microbiol Infect. 2023 Mar;29(3):388.e1-388.e8. doi: 10.1016/j.cmi.2022.10.009. Epub 2022 Oct 14. PMID: 36252789; PMCID: PMC9562615.
- Gaborit B, Fernandes S, Loubet P, Ninove L, Dutour A, Cariou B, et al; ANRS0001S COV-POPART study group. Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort. Metabolism. 2023 May;142:155412. doi: 10.1016/j.metabol.2023.155412. Epub 2023 Jan 31. PMID: 36731720; PMCID: PMC9886395 .
- Loubet P, Lelievre JD, François A, Botelho-Nevers E, Chidiac C, et al; ANRS0001s COV-POPART study group. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART. Int J Infect Dis. 2024 Sep;146:107110. doi: 10.1016/j.ijid.2024.107110. Epub 2024 May 31. PMID: 38825164.
- Chalouni M, Loubet P, Lhomme E, Ninove L, Barrou B, Blay JY, et al; ANRS0001S COV-POPART study group. Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants. BMC Infect Dis. 2024 Sep 27;24(1):1049. doi: 10.1186/s12879-024-09861-5. PMID: 39333909; PMCID: PMC11429529.
Pathologie
Covid-19
Population
Adult, teenager, child
Sample
RNA, plasma, whole blood, serum, saliva
Status
Completed
